Ingevity (NGVT) Projected to Post Quarterly Earnings on Wednesday

Ingevity (NYSE:NGVT) is expected to be posting its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect Ingevity to post earnings of $0.74 per share and revenue of $257.2670 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 10:00 AM ET.

Ingevity Price Performance

Shares of NGVT opened at $72.20 on Monday. The stock has a 50 day simple moving average of $65.98 and a 200 day simple moving average of $58.55. Ingevity has a 52-week low of $28.49 and a 52-week high of $77.46. The company has a debt-to-equity ratio of 8.39, a quick ratio of 0.80 and a current ratio of 1.27. The firm has a market capitalization of $2.60 billion, a PE ratio of -39.67 and a beta of 1.34.

Hedge Funds Weigh In On Ingevity

A number of large investors have recently modified their holdings of NGVT. State of Tennessee Department of Treasury grew its holdings in Ingevity by 25.3% during the fourth quarter. State of Tennessee Department of Treasury now owns 20,881 shares of the company’s stock worth $1,236,000 after purchasing an additional 4,219 shares during the period. XTX Topco Ltd lifted its position in shares of Ingevity by 409.3% in the fourth quarter. XTX Topco Ltd now owns 21,075 shares of the company’s stock valued at $1,247,000 after buying an additional 16,937 shares during the last quarter. Susquehanna Portfolio Strategies LLC bought a new position in shares of Ingevity during the 4th quarter worth approximately $1,112,000. Summit Securities Group LLC acquired a new position in shares of Ingevity during the 4th quarter worth approximately $178,000. Finally, Evolve Private Wealth LLC acquired a new position in shares of Ingevity during the 4th quarter worth approximately $319,000. 91.59% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. BMO Capital Markets upped their price target on shares of Ingevity from $64.00 to $70.00 and gave the company an “outperform” rating in a report on Wednesday, December 10th. Zacks Research raised shares of Ingevity to a “hold” rating in a research note on Tuesday, December 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ingevity in a report on Thursday, January 22nd. Wells Fargo & Company boosted their price target on Ingevity from $60.00 to $65.00 and gave the company an “equal weight” rating in a report on Wednesday, January 28th. Finally, Wall Street Zen cut Ingevity from a “strong-buy” rating to a “buy” rating in a research report on Saturday. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $67.50.

Ingevity Company Profile

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.